Cell Impact (CI) Q1 2025 earnings summary

Executive summary

• Net sales for Q1 2025 were SEK 1.9 million, a 67% decrease year-over-year, mainly from tooling and development projects; flow plate sales were lower than expected.

• Operating loss (EBIT) improved slightly to SEK -20.8 million from SEK -22.0 million year-over-year.

• The company intensified efforts to secure additional financing due to delayed orders and a rapid global economic slowdown.

• Cost reductions implemented in 2023 and 2024 have made operations more cost-efficient, but fixed costs remain significant.

Financial highlights

• Net sales: SEK 1.9 million (Q1 2024: SEK 5.8 million).

• Operating loss (EBIT): SEK -20.8 million (Q1 2024: SEK -22.0 million).

• Net loss: SEK -21.5 million (Q1 2024: SEK -23.4 million).

• Cash flow from operating activities: SEK -10.8 million (Q1 2024: SEK -36.7 million).

• Cash and cash equivalents at period end: SEK 5.8 million (Q1 2024: SEK 47.6 million).

Outlook and guidance

• The company is actively pursuing new sales initiatives and reviewing its cost base to attract new orders and secure operations.

• Additional financing is necessary to support ongoing operations and lay the foundation for future volumes.

• No dividend is planned in the near future; profits will be reinvested for expansion.